Zenas BioPharma, Inc.
ZBIO
$7.80
-$0.63-7.47%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.00M | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.00M | -- | -- | -- | 0.00 |
| Cost of Revenue | 49.16M | 33.53M | 33.81M | 22.65M | 20.42M |
| Gross Profit | -44.16M | -33.53M | -33.81M | -22.65M | -20.42M |
| SG&A Expenses | 11.47M | 7.45M | 5.90M | 4.93M | 4.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.62M | 40.98M | 39.70M | 27.58M | 24.78M |
| Operating Income | -55.62M | -40.98M | -39.70M | -27.58M | -24.78M |
| Income Before Tax | -52.18M | -38.61M | -37.98M | -27.80M | -24.29M |
| Income Tax Expenses | 429.00K | -- | -- | -- | 301.00K |
| Earnings from Continuing Operations | -52.60M | -38.61M | -37.98M | -27.80M | -24.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.60M | -38.61M | -37.98M | -27.80M | -24.59M |
| EBIT | -55.62M | -40.98M | -39.70M | -27.58M | -24.78M |
| EBITDA | -55.59M | -40.95M | -39.67M | -27.55M | -24.75M |
| EPS Basic | -1.25 | -5.02 | -24.23 | -17.89 | -15.95 |
| Normalized Basic EPS | -0.77 | -3.13 | -15.14 | -11.18 | -9.73 |
| EPS Diluted | -1.25 | -5.02 | -24.23 | -17.89 | -15.95 |
| Normalized Diluted EPS | -0.77 | -3.13 | -15.14 | -11.18 | -9.73 |
| Average Basic Shares Outstanding | 41.93M | 7.70M | 1.57M | 1.55M | 1.54M |
| Average Diluted Shares Outstanding | 41.93M | 7.70M | 1.57M | 1.55M | 1.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
